These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

232 related articles for article (PubMed ID: 11579244)

  • 1. Bone mineral loss through increased bone turnover in HIV-infected children treated with highly active antiretroviral therapy.
    Mora S; Sala N; Bricalli D; Zuin G; Chiumello G; Viganò A
    AIDS; 2001 Sep; 15(14):1823-9. PubMed ID: 11579244
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Longitudinal changes of bone mineral density and metabolism in antiretroviral-treated human immunodeficiency virus-infected children.
    Mora S; Zamproni I; Beccio S; Bianchi R; Giacomet V; Viganò A
    J Clin Endocrinol Metab; 2004 Jan; 89(1):24-8. PubMed ID: 14715822
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Different impact of NNRTI and PI-including HAART on bone mineral density loss in HIV-infected patients.
    Madeddu G; Spanu A; Solinas P; Babudieri S; Calia GM; Lovigu C; Mannazzu M; Nuvoli S; Piras B; Bagella P; Mura MS; Madeddu G
    Eur Rev Med Pharmacol Sci; 2015 Dec; 19(23):4576-89. PubMed ID: 26698255
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [The impact of highly active antiretroviral therapy on bone mineral density in human immunodeficiency virus infected patients].
    Guo FP; Yu XB; Luo L; Han Y; Qiu ZF; Zuo LY; Li YL; Yu W; Li TS
    Zhonghua Nei Ke Za Zhi; 2010 Aug; 49(8):649-52. PubMed ID: 20979781
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Influence of long-term highly active antiretroviral therapy on bone mineral density in HIV/AIDS patients].
    Su YB; Xie J; Han Y; Qiu ZF; Li YL; Song XJ; Yu W; Li TS
    Zhonghua Yi Xue Za Zhi; 2012 May; 92(17):1155-8. PubMed ID: 22883000
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Relationship between low bone mineral density and highly active antiretroviral therapy including protease inhibitors in HIV-infected patients.
    Fernández-Rivera J; García R; Lozano F; Macías J; García-García JA; Mira JA; Corzo JE; Gómez-Mateos J; Rueda A; Sánchez-Burson J; Pineda JA
    HIV Clin Trials; 2003; 4(5):337-46. PubMed ID: 14583850
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Bone turnover and bone mineral density in HIV-1 infected Chinese taking highly active antiretroviral therapy -a prospective observational study.
    Zhang L; Su Y; Hsieh E; Xia W; Xie J; Han Y; Cao Y; Li Y; Song X; Zhu T; Li T; Yu W
    BMC Musculoskelet Disord; 2013 Jul; 14():224. PubMed ID: 23899016
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Bone mass loss and vitamin D metabolism impairment in HIV patients receiving highly active antiretroviral therapy.
    Madeddu G; Spanu A; Solinas P; Calia GM; Lovigu C; Chessa F; Mannazzu M; Falchi A; Mura MS; Madeddu G
    Q J Nucl Med Mol Imaging; 2004 Mar; 48(1):39-48. PubMed ID: 15195003
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Reduced bone mineral density in human immunodeficiency virus-infected patients and its association with increased central adiposity and postload hyperglycemia.
    Brown TT; Ruppe MD; Kassner R; Kumar P; Kehoe T; Dobs AS; Timpone J
    J Clin Endocrinol Metab; 2004 Mar; 89(3):1200-6. PubMed ID: 15001610
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Stable bone mineral density over 6 years in HIV-infected men treated with highly active antiretroviral therapy (HAART).
    Bolland MJ; Grey A; Horne AM; Briggs SE; Thomas MG; Ellis-Pegler RB; Gamble GD; Reid IR
    Clin Endocrinol (Oxf); 2012 May; 76(5):643-8. PubMed ID: 22040002
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Osteopenia in HIV-infected men: association with asymptomatic lactic acidemia and lower weight pre-antiretroviral therapy.
    Carr A; Miller J; Eisman JA; Cooper DA
    AIDS; 2001 Apr; 15(6):703-9. PubMed ID: 11371684
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Alterations in circulating osteoimmune factors may be responsible for high bone resorption rate in HIV-infected children and adolescents.
    Mora S; Zamproni I; Cafarelli L; Giacomet V; Erba P; Zuccotti G; Viganò A
    AIDS; 2007 May; 21(9):1129-35. PubMed ID: 17502723
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of highly active antiretroviral therapy on fat, lean, and bone mass in HIV-seropositive men and women.
    McDermott AY; Shevitz A; Knox T; Roubenoff R; Kehayias J; Gorbach S
    Am J Clin Nutr; 2001 Nov; 74(5):679-86. PubMed ID: 11684538
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Multifactorial relations between HIV, HAART and bone metabolism].
    Borderi M
    Infez Med; 2006 Sep; 14(3):117-24. PubMed ID: 17127825
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Bone measures in HIV-1 infected children and adolescents: disparity between quantitative computed tomography and dual-energy X-ray absorptiometry measurements.
    Pitukcheewanont P; Safani D; Church J; Gilsanz V
    Osteoporos Int; 2005 Nov; 16(11):1393-6. PubMed ID: 15702261
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Highly active antiretroviral-treated HIV-infected children show fat distribution changes even in absence of lipodystrophy.
    Brambilla P; Bricalli D; Sala N; Renzetti F; Manzoni P; Vanzulli A; Chiumello G; di Natale B; Viganò A
    AIDS; 2001 Dec; 15(18):2415-22. PubMed ID: 11740192
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The relationship of biochemical markers of bone turnover to bone density changes in postmenopausal women: results from the Postmenopausal Estrogen/Progestin Interventions (PEPI) trial.
    Marcus R; Holloway L; Wells B; Greendale G; James MK; Wasilauskas C; Kelaghan J
    J Bone Miner Res; 1999 Sep; 14(9):1583-95. PubMed ID: 10469288
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prevalence and risk factors of low bone mineral density among perinatally HIV-infected Thai adolescents receiving antiretroviral therapy.
    Puthanakit T; Saksawad R; Bunupuradah T; Wittawatmongkol O; Chuanjaroen T; Ubolyam S; Chaiwatanarat T; Nakavachara P; Maleesatharn A; Chokephaibulkit K
    J Acquir Immune Defic Syndr; 2012 Dec; 61(4):477-83. PubMed ID: 22918157
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Alendronate reduces bone resorption in HIV-associated osteopenia/osteoporosis.
    Guaraldi G; Orlando G; Madeddu G; Vescini F; Ventura P; Campostrini S; Mura MS; Parise N; Caudarella R; Esposito R
    HIV Clin Trials; 2004; 5(5):269-77. PubMed ID: 15562367
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Decreased bone mineral density in HIV-infected patients is independent of antiretroviral therapy.
    Bruera D; Luna N; David DO; Bergoglio LM; Zamudio J
    AIDS; 2003 Sep; 17(13):1917-23. PubMed ID: 12960824
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.